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patient. Acute and late toxicity were analyzed, according to 
CTCAE toxicity scale (v. 4.0).  
 
Results: The median follow-up was 14.5 months. Most of 
patients received 30 Gy, in 3 fractions, on alternative days: 
all the patients completed the prescribed SBRT 
treatment.Fifteen patients (71%) received androgen 
deprivation therapy concomitant to SBRT.SBRT was well 
tolerated: only 1 patient experienced G2 acute rectal toxicity 
but we didn’t observe any severe acute or late toxicity ( ≥G3). 
Despite the short follow up, local control was 100%, distant 
control was 79% (6/21).All these recurrences were nodal and 
all out of SBRT field: in 2 of these 6 patients a new SBRT 
course was delivered (30 Gy in 3 fractions) while in the other 
hormonal therapy was proposed. At the moment of analysis, 
all patients were alive. 
 
Conclusion: Our experience shows that SBRT for isolated 
nodal relapse from prostate cancer is a safe treatment, 
offering a low toxicity profile and an excellent tumor local 
control. More data and a longer follow up are needed. 
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Purpose or Objective: Most studies demonstrate that local 
salvage therapy after EBRT may provide long-term local 
control in appropriately selected pts, although toxicity is 
often significant.In these pts, PET/CT with [11C]choline may 
accurately detect the presence of recurrence.We 
investigated the role of [11C]choline PET/CT for target 
volume selection and delineation in pts with recurrent 
prostate cancer following EBRT for a salvage tailored 
Cyberknife Stereotactic Hypofractionated 
Radiotherapy(SBRT) treatment. 
 
Material and Methods: From December 2012 to April 2015,22 
pts with initial disease category defined as 
low(2),intermediate(6) high (14),in accordance with NCCN 
2008 guidelines,median age of 74 years(range 62-89) and an 
history of locally-recurrent prostate cancer following EBRT 
were referred to our Department for salvage Cyberknife 
SBRT. The diagnosis of a clinically evident recurrence of 
prostate cancer was based on biochemical progression and 
imaging studies. Median iPSA was 22,7 ng.ml(4,9-88 
ng.ml),EBRT doses ranged from 74 to 79.2 Gy(median 76Gy) 
and the median interval time between relapse diagnosis and 
salvage Cyberknife treatment was 60 months(range 19-
139).The median pre-reirradiation PSA was 4,64 ng/ml (range 
2,23-13,04 ng/ml). CT scan and MRI with T1-T2 sequences 
were performed and [11C]choline PET/CT images were fused 
for prostate target volume delineation.5 pts received 3 
fractions of 10 Gy (total dose 30 Gy), 17 pts received 3 
fractions of 12 Gy (total dose 36 Gy) delivered to the PET 
positive prostate node (median volume of 14,3 cc-range 5,75-
65,04) in the respect of organ at risk constrains. 
 
Results: The treatment was well tolerated with no RTOG 
grade 3 acute or late toxicity. With a median follow up of 17 
months (range 6-35) we observed the following results: no in 
field recurrence, with a local control of 100%. In 4 pts, 
respectively at 11, 14, 16 and 22 months after treatment 
(median time 15 Months), a [11C]choline PET/CT detect a 
local recurrence with the evidence of a new positive prostate 
node outside the irradiated field requiring a second 
Cyberknife salvage treatment. 
 
Conclusion: Advances in modern imaging show promises in 
the management of prostate cancer at the different stage 
(diagnosis, treatment planning and follow up). According to 
available literature [11C]choline PET/CT is not clinically 
recommendable to plan target volume, nevertheless ,our 
promising data suggest a potential role of [11C]choline 
PET/CT as an image guide tool for the focal irradiation of 
prostate cancer relapse. 
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Purpose or Objective: To analyze the dosimetric impact on 
long term gastro-intestinal (GI) toxicity of two sequential 
dose escalation regimens of twice weekly 4 Gy/fractions 
hypofractionated intensity-modulated radiotherapy (IMRT) 
delivered within a protracted overall treatment time of 6.5 
and 7 weeks, respectively. 
 
Material and Methods: Clinical and dosimetric data on 96 
prostate cancer patients with cT1c-T3a disease and nodal 
involvement risk ≤20% (Roach index) treated twice-weekly to 
the prostate +/- seminal vesicles with two sequential dose-
escalated IMRT schedules of 56 Gy (14 x 4 Gy, n=28) from 
2003 to 2007 and 60 Gy (15 x 4 Gy, n=68) from 2006 to 2010 
were analyzed. The corresponding NTD2Gy for an α/β ratio of 
1.5 and 3 Gy were 88 and 78 Gy for the 56 Gy group, and 94 
and 84 Gy for the 60 Gy group, respectively. The planning 
target volume (PTV) consisted of an anisotropic expansion of 
10 mm around the prostate, except 6-mm posteriorly. Patient 
repositioning was made with bone-matching on portal images 
or body markers registration. GI toxicities were scored using 
the CTCAE v3.0 grading scale. 
 
Results: Among the 96 analyzed patients, the 5-year grade ≥2 
late GI toxicity-free survival was similar in patients treated 
with 56 Gy compared to those treated with 60 Gy (92.6±5.1% 
vs. 85.0±5.1%, p=0.533). Mean volumes of rectum receiving 
more than 50 Gy (V50Gy, equivalent to V70Gy NTD2Gy, α/β=3 
Gy) and 54 Gy (V54Gy, equivalent to V75Gy NTD2Gy) were 
15.8% vs. 20.9% (p=0.001) and 4.2% vs. 13.8% (p=0.0001) for 
the 56 and 60 Gy groups, respectively. A V50Gy ≤ 19% 
(median 19.2%, range 4.4%-37.8%) was achieved in 67.9% and 
38.2% of the patients treated with 56 and 60 Gy, 
respectively. A V50Gy >19% correlated with a 5-year grade ≥2 
late-GI toxicity-free survival of 80.8±6.3%, significantly worse 
than patients with a V50Gy ≤ 19Gy (95.3±3.2%, p=0.031).  
 
Conclusion: Independently from the dose prescription, a 
V50Gy ≤ 19% may result in a better long term rectal toxicity 
profile in patients treated with a hypofractionated IMRT 
schedule of 56 or 60 Gy in 4 Gy fractions. As for 
normofractionated schedules the QUANTEC dose constraint 
V70Gy<20% for the rectum seems to be a strong predictive 
factor of late GI toxicity for hypofractionated regimens as 
well. 
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Purpose or Objective: To report early outcome of 
hypofractionated radiotherapy for prostate cancer patients 
using a simultaneous integrated boost strategy (SIB) focusing 
on acute genitourinary (GU) and acute and late 
gastrointestinal toxicity (GI). 
 
Material and Methods: Between 01/2012 and 06/2014 
ninety-seven low (n=13) -, intermediate (n=22) - and high-risk 
(n=45)- prostate cancer patients were treated with 
hypofractionated radiotherapy using VMAT/IMRT and SIB. It 
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consisted of 65.75 Gy to the prostate gland+seminal vesicles 
(2.63 Gy/fx) and 45 Gy to the pelvic nodes (1.8 Gy daily) 
when needed, delivered in 25 fractions. All patients 
underwent daily image guidance with cone-beam computed 
tomography. Sixty-six percent of the patients received 
implanted gold markers (64/97). Acute and late 
gastrointestinal- and genitourinary toxicity was recorded 
according to the Common Terminology Criteria for Adverse 
Events 4.0. Chi-square test and univariate regression analysis 
were used to determine correlation of categorical and 
continuous data at the p<0.05 significance level. 
 
Results: During a median follow-up of 23 (range: 4-44) 
months, 7/97 biochemical failures (7%) were observed. The 
frequency of ≥Gr. 2 acute gastrointestinal (GI) and 
genitourinary (GU) toxicities were 8% (8/97) and 45% (44/97) 
including 6% Gr. 3 bladder urgency and nycturia (6/97). Late 
≥Gr. 2 GI toxicities of 14 % (13/97) were mainly rectal 
bleeding and chronic proctitits. Correlation was found 
between lymph node irradiation (p=0.008) and late rectal 
toxicities, while for other patient characteristics including 
the presence of gold markers (p=0.097) or smoking (p=0.99) 
did not appear to affect such adverse event. d univariate 
regression analysis were used to determine correlation of 
categorical and continuous data at the p<0.05 significance 
level. 
 
Conclusion: Our experiences suggest that moderate 
hypofractionation with SIB technique is safe with moderate 
acute side effects. Longer follow-up and higher number of 
patients is warranted to confirm these results in long term. 
8) and late rectal toxicities, while for other patient 
characteristics including the presence of gold markers 
(p=0.097) or smoking (p=0.99) did not appear to affect such 
adverse event. d univariate regression analysis were used to 
determine correlation of categorical and continuous data at 
the p<0.05 significance level. 
 
EP-1367  
IMRT from 70 Gy to 80 Gy in prostate cancer: clinical and 
dosimetric predictors of late toxicity 
M. Jolnerosvki
1Institut de Cancérologie de Lorraine, Radiation Oncology, 
Vandoeuvre les Nancy, France 
1, J. Salleron2, V. Beckendorf1, D. Peiffert1, 
A.S. Baumann1, V. Bernier-Chastagner1, V. Marchesi3, S. 
Huger3, G. Vogin1, C. Chira1 
2Institut de Cancérologie de Lorraine, Biostatistics, 
Vandoeuvre les Nancy, France 
3Institut de Cancérologie de Lorraine, Physics, Vandoeuvre 
les Nancy, France 
 
Purpose or Objective: Evaluate grade ≥ 2 overall late rectal 
and bladder toxicity in patients (pts) with localized prostate 
cancer (CaP) treated by IMRT. Identify predictors of 
radiation-induced toxicity and analyze biochemical 
progression free survival (bPFS). 
 
Material and Methods: A total of 276 pts were treated 
between 2000 and 2010 with 70Gy (10.8%), 74 Gy (63.9%) and 
80 Gy (25.3%), using static 5-field IMRT without pelvic 
irradiation. Short or longue-course deprivation (ADT) was 
prescribed in 25.4 % and 20.7%, respectively. The toxicity was 
described using the Common Terminology Criteria for Adverse 
Events (CTCAE) v4.0 scale. Cox regression models addressed 
tumor (T stage, Gleason score, PSA) and patient 
characteristics (age, diabetes, previous abdominal or pelvic 
surgery, transurethral prostate resection, anticoagulation 
treatment, hypertension, coronary insufficiency and 
International Prostate Symptom Score-IPSS) as well as 
dosimetric predictors of late grade ≥ 2 overall toxicity.  
An analysis of dosimetry data was only performed in the 74-
Gy arm. Our institutional HDV constraints for rectal wall 
(maximal dose ≤74 Gy, V68Gy <25%, V45Gy <45%) and bladder 
wall (maximal dose ≤74 Gy; V50Gy <40%, V65Gy <25%) were 
tested as potential predictors for late toxicity.  
Biochemical progression free survival was analyzed only in pts 
without ADT. 
 
Results: The median follow-up was 53.1 months (range, 6-
150). There was no grade ≥ 4 toxicity. The use of ADT was 
not found to be predictive. The 5-year rectal and bladder 
toxicity-free survival was 93.8 % (95% CI, 89.8%-96.2%) and 
75.2 % (95% CI, 68.7%-80.5%) respectively.  
In multivariate analysis (MvA) only the dose (80Gy vs 74 Gy 
and 70Gy) increased the risk of overall rectal toxicity (hazard 
ratio [HR]=2.96; 1.07- 8.20). The non-compliance to our 
constraints on rectal wall was not a significant predictor of 
rectal toxicity.  
IPSS at baseline ≥ 8 (hazard ratio [HR]=2.60;1.47 -4.62), 
delivered maximum dose (Dmax) ≥ 74Gy (HR=2.09;1.04 -4.17) 
and dose delivered in ≥ 2% of bladder (D2%) ≥ 73Gy 
(HR=3.33;1.37-8.07) were found to be predictors of bladder 
toxicity.  
The 5-year bPFS was 81.0% (74.5%; 86.0%). D’Amico low 
(HR=0.09; 0.01- 0.69]) and intermediate risk group (HR=0.49; 
0.28-0.88) as well as PSA nadir ≥ 0.2 ng/ml (HR =1.79; 1.01 -
3.21) were predictive of biochemical relapse. 
 
Conclusion: The rate of late rectal toxicity increased with 
higher doses, while Dmax ≥ 74Gy, D2% ≥ 73Gy and baseline 
IPSS ≥ 8 increased bladder toxicity. 
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Purpose or Objective: A relative new method to decrease 
the risk of rectal complications during prostate radiotherapy 
treatments consists of the implantation of a device, an 
absorbable hydrogel or saline filled balloon, between the 
prostate and the anterior rectum wall: so called rectum 
spacers (RS). Nevertheless the implantation of a RS is 
relatively expensive and invasive. Therefore a decision 
support system to identify beforehand whether a specific 
patient will benefit from a RS and whether it will be cost 
efficient would be very beneficial. We have developed a 
novel method to predict the CT images with a ‘virtual’ RS 
through non-rigid deformations based on a CT scan without 
RS to be integrated into a decision support system. 
 
Material and Methods: A patient dataset consisting of 16 
prostate cancer patients with CT imaging prior and 3-5 days 
after a gel RS implantation (SpaceOAR™ System, Augmenix 
Inc.) was used. The median inserted gel volume was 10.5 cc. 
Gel contours of the first 8 patients were used as a training 
set to derive the spatial deformation model of the RS. The 
contours of the RS were registered rigidly according to their 
centre and an average deformation map was created. The 
overlapping volumes of RS of different patients having a 
probability of >3 contour corresponded with a volume of 10 
cc, and was used to derive the deformation model of the RS. 
From this model, a deformation field was calculated that 
mimics the expansion of the RS between the prostate and the 
rectum. The CT images of the remaining 8 patients were used 
to validate the virtual RS model, for this the distance 
between the rectum and the prostate was compared for the 
virtual RS and the actual RS .  
 
Results: An example of the virtual RS is shown in the figure 
where the contours of the real RS and virtual RS show a good 
overlap (DICE = 0.63). The average minimum distances 
between the prostate and rectum of all 8 patients in the 
validation set increased with 3.7±2.4 (1SD) mm when the 
virtual RS was applied. For the real RS the average increase 
in minimum distance was 5.4±2.7 mm. The mean distances 
between the prostate and rectum without RS was 15.8±3.2 
mm, with the virtual RS this was 19.5±3.3 mm comparable to 
the real RS 22.0±4.3 mm. 
 
